Quest Diagnostics Stock (DGX): $190 Price Target From Deutsche Bank

By Amit Chowdhry ● Jan 15, 2022
  • The shares of Quest Diagnostics Inc (NYSE: DGX) have received a price target of $190 from Deutsche Bank. These are the details.

The shares of Quest Diagnostics Inc (NYSE: DGX) have received a price target of $190 from Deutsche Bank. And Deutsche Bank analyst Pito Chickering increased the price target on Quest Diagnostics from $160 while maintaining a “Buy” rating on the company shares. 

Chickering had increased the fourth-quarter and first-quarter estimates to account for additional COVID tests.

Earlier this week, Quest Diagnostics signaled an upbeat 2021 profit as COVID-19 testing volumes had surged with the spread of the omicron coronavirus variant in the U.S.

Quest performed over 120,000 PCR tests per day in the last couple of weeks of 2021 and over 150,000 tests a day at the beginning of 2022.

“We saw a steep increase in our volumes in the fourth quarter, particularly the last two weeks in December, and it continues into January,” said Quest Diagnostics Chief Executive Officer Steve Rusckowski at the annual J.P. Morgan Health Care conference via Reuters.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.